Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Calderwood, MA
David J. Calderwood, Framingham, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20080242862 | Novel imidazo based heterocycles - The present invention is directed to novel imidazopyrazine compounds useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers. | 10-02-2008 |
| 20080249305 | Novel imidazole based heterocycles - The present invention is directed to novel imidazopyrazine compounds useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers. | 10-09-2008 |
| 20090270402 | Novel triazolopyridazines - The present invention is directed to novel compounds of formula (I) | 10-29-2009 |
| 20090312338 | Novel Tricyclic Compounds - The invention provides a compound of Formula (I) | 12-17-2009 |
| 20100041676 | Kinase inhibitors - The present application is directed to compounds of the formula (I) | 02-18-2010 |
| 20100069371 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS - Compounds having the formula | 03-18-2010 |
| 20110190489 | Novel Tricyclic Compounds - The invention provides a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), or (Il) as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions. | 08-04-2011 |
| 20110311474 | Novel Tricyclic Compounds - The invention provides compounds of Formula (I) and Formula (II) | 12-22-2011 |
Emily F. Calderwood, Framingham, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20120015942 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF - This invention provides compounds of formula (I): | 01-19-2012 |
| 20120015943 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF - This invention provides compounds of formula (I): | 01-19-2012 |
Stephen B. Calderwood, Wellesley, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090297548 | IMMUNOGENIC COMPOSITIONS COMPRISING ANTHRAX SPORE-ASSOCIATED PROTEINS - Compositions and methods for treating a | 12-03-2009 |
Stuart K Calderwood, Chestnut Hill, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090062222 | Methods for Sensitizing Cancer Cells to Inhibitors - The present invention is based on the discovery that inactivation of the heat shock response in cancer cells significantly enhances their sensitivity to proteasome and Hsp90 inhibitors. The inventors have discovered novel compounds which exhibit low toxicity, inhibit the heat shock protein response and sensitize cancer cells to anti-cancer therapies. In general, the heat shock protein inhibitors of the present invention share a common structure, namely a 2H-benzo[a]quinolizine tricyclic ring. Also encompassed are methods for a high throughput screen to identify heat shock inhibitors that sensitize cancer cells to anti-cancer therapies. | 03-05-2009 |
| 20100247562 | Complexes Derived from Heterohybrid Cells and Uses Thereof - The present invention relates, generally, to pharmaceutical compositions comprising Heat Shock Proteins (HSPs) and HSP complexes recovered from heterohybrid cells that are generated from the fusion of a first type of cell (Type I) with a second type of cell (Type II). In further embodiments, the present invention relates to preparing HSPs and/or HSP complexes recovered from heterohybrid, and to methods to treat and/or prevent diseases, such as cancer and infectious diseases by administering a pharmaceutical composition comprising a HSP and/or HSP complex recovered from heterohybrid cells that are generated from the fusion of a first type of cell (Type I) with a second type of cell (Type II). | 09-30-2010 |
Stuart K. Calderwood, Brookline, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20080214844 | Icaritin and desmethylicaritin as anti-cancer agents - The antiproliferative effects of Icaritin or Desmethylicaritin on cancer cell lines, both in vitro, and in vivo, are disclosed. Experimental data show that Icaritin and Desmethylicaritin dramatically inhibit the growth of most malignant cells. In addition, both Icaritin and Desmethylicaritin have significant Anti-agiogenesis properties, inhibiting or eliminating entirely the development of new malignant cells. Further, no obvious side effects including nausea, hair loss or body weight loss were found in the animals treated with Icaritin or Desmethylicaritin, making both highly effective anti cancer drugs. | 09-04-2008 |